5) (Amended) [Use] A method according to claim 4 wherein the [peptide or peptide fragment] binding member is from 5 to 40 amino acids in length.

6) (Amended) [Use] A method according to [any one of] claim[s] 3 [to 5] wherein the [peptide or peptide fragment] binding member is derived from a CCT substrate.

7) (Amended) [Use] A method according to claim 6 wherein the substrate is selected from the group consisting of actin, tubulin or cyclin.

8) (Amended) [Use] A method according to claim 7 wherein the substrate is actin.

A1 amend

9) (Amended) [Use] A method according to [any one of] claim[s] 3 [to 8] wherein the [peptide or peptide fragments] binding member comprises [any one of the] a sequence[s] selected from the group of sequences shown in Figure 10.

10) (Amended) [Use] A method according to [any one of] claim[s 3 to] 9 wherein the [peptide or peptide fragment] binding member comprises the amino acid sequence GRPRH.

12) (Amended) A method according to claim 11 wherein the binding member is selected from the group consisting of a peptide [or] and a peptide fragment.

13) (Amended) A method according to claim [11 or claim] 12 wherein the candidate binding member is a peptide or peptide fragment having an amino acid sequence corresponding to the amino acid sequence of a CCT apical domain.

16) A method according to [any one of] claim[s] 12 [to

A2 Con't

14] wherein the peptide or peptide fragment comprises [any one of the] a sequence[s] selected from the group of sequences [as] shown in Fig. 10.

17) A method according to [any one of] claim 11 [to 16] further comprising the step of immobilising the candidate binding member on a solid phase prior to contacting with the CTT apical domain.

A2 cncld.

18) (Amended) A method according to [any one of] claim[s] 11 [to 17] further comprising the step of modifying the candidate binding member to improve its binding with the CCT apical domain.

19) (Amended) A method according to [any one of] claim 11 [to 18] wherein binding between the candidate binding member and the CCT apical domain is determined by a competitive assay.

A3

23) (Amended) A binding member according to claim 22 comprising any one of the amino acid sequences selected from the group of sequences [as] shown in Fig. 10.

25) (Amended) A binding member according to [any one of] claim[s] 20 [to 24] [for use in] having binding affinity [to] for a CCT complex such that it blocks a substrate binding site on said CCT complex thereby effecting the biological activity of the CCT complex.

A4

26) (Amended) A binding member according to [any one of] claim[s] 20 [to 25] linked to a coupling partner.

28) (Amended) A binding member according to [any one

A5 cmt

of] claim[s] 20 [to claim 27] for use in medical treatment.

29) (Amended) [Use of a binding member according to any one of claims 20 to 27 in the preparation of a] A medicament for the treatment of cancer cells, said medicament comprising a binding member as claimed in claim 20, [wherein the] said medicament [is] being administered to said cells to effect the biological activity of a CCT complex within the cell.

A5 cncld

30) [Use] A medicament according to claim [3]29 wherein the medicament further comprises a cancer drug.

31) (Amended) A method for screening for mimetics of binding members according to [any one of] claim[s] 20 [to 27] comprising exposing said binding members and a candidate mimetic to a CCT substrate binding site or active portion thereof, so that the candidate mimetic and the binding member compete to bind to the CCT substrate binding site; and detecting the extent of binding of the candidate mimetic or the binding member to the CCT substrate binding site.

35) (Amended) A method according to [any one of] claim[s] 27 [to 34] wherein the binding member or the candidiate mimetic is immobilised on a solid support.

A6 cn't

36) (Amended) A method according to [any one of] claim[s] [31 to] 35 wherein the extent of binding of the candidate mimetic is detected by labelling the CCT substrate binding site complex or active portion thereof or by using a labelled antibody capable of binding to the CCT substrate binding domain.

37) (Amended) A method according to [any one of]

claim[s] [31 to] 36 wherein the CCT substrate binding site comprises the sequence corresponding to residues D219 to N394 of CCT6.

A6 cncld.

38) (Amended) A pharmaceutical composition comprising a binding member according to [any one of] claim 20 [to 28] in combination with a pharmaceutically acceptable carrier.

42) (Amended) A host cell comprising the vector according to claim 41 [or the nucleic acid according to claim 40].

A7

Please add the following new claim:

A8

43) A host cell comprising the nucleic acid according to claim 40.

REMARKS

The purpose of this preliminary amendment is to remove any existing multiple dependencies from the claims.

Favorable consideration leading to prompt allowance of the present application is respectfully requested.

Respectfully submitted,
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By Kathleen D Rigaut

Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100
Facsimile: (215) 563-4044